Loading data for PMN — first visit, this takes a few seconds.
ProMIS Neurosciences Inc. (PMN)
NasdaqCM: PMN
· Real-Time Price · USD
15.36
+0.56 (3.78%)
At close: Aug 25, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
ProMIS Neurosciences Inc. (PMN) Stock Price, Analysis & Data
3.78% (1D)
No data available
| Bid | 10.95 |
| Market Cap | 137.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.23M |
| -0.22 | |
| -12.62 | |
| n/a | |
| -3.28 | |
| P/B (ttm) | 2.79 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 7, 2025 |
| Ask | 19.07 |
| Volume | 60,642 |
| Avg. Volume (20D) | 82,246 |
| Open | 15.00 |
| Previous Close | 14.80 |
| Day's Range | 14.50 - 15.36 |
| 52-Week Range | 6.27 - 27.40 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 10, 2007
Employees 10
Stock Exchange NasdaqCM
Ticker Symbol PMN
Financial Performance
In 2025, ProMIS Neurosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -39.72M, a decrease of -1,529.33%.
Financial StatementsEarnings Surprise
ProMIS Neurosciences has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.78 exceeds estimates by 0.12, with 75.78% YoY growth.
ProMIS Neurosciences Inc. is scheduled to release its earnings on Aug 7, 2025, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2